Orthofix Medical Inc. (NASDAQ: OFIX)

Sector: Healthcare Industry: Medical Devices CIK: 0000884624
Market Cap 530.71 Mn
P/B 1.20
P/E -4.46
P/S 0.65
ROIC (Qtr) -15.28
Div Yield % 0.00
Rev 1y % (Qtr) 4.59
Total Debt (Qtr) 175.27 Mn
Debt/Equity (Qtr) 0.40
Add ratio to table...

About

Orthofix Medical Inc. (OFIX) is a leading global company in the medical device industry, specializing in the provision of a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. The company's products are distributed in over 60 countries worldwide, with a global research and development, commercial, and manufacturing footprint that includes facilities and offices in the United States, Canada, Europe, and Brazil. Orthofix's business is...

Read more

Investment thesis

Bull case

  • Healthy cash reserves of 65.95M provide 81.01x coverage of short-term debt 814000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 562.03M provides 3.21x coverage of total debt 175.27M, indicating robust asset backing and low credit risk.
  • Tangible assets of 562.03M provide robust 5.18x coverage of other current liabilities 108.57M, indicating strong asset backing.
  • Cash reserves of 65.95M provide solid 1.18x coverage of other non-current liabilities 55.82M, indicating strong liquidity.
  • Tangible assets of 562.03M provide robust 3.52x coverage of current liabilities 159.85M, showing strong asset backing.

Bear case

  • Operating cash flow of 29.38M barely covers its investment activities of (24.86M), with a coverage ratio of -1.18, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (24.86M) provide weak support for R&D spending of 69.28M, which is -0.36x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of 29.38M shows concerning coverage of stock compensation expenses of 28.64M, with a 1.03 ratio indicating potential earnings quality issues.
  • Free cash flow of (2.90M) provides weak coverage of capital expenditures of 32.28M, with a -0.09 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (90.27M) show weak coverage of depreciation charges of 80.24M, with a -1.13 ratio indicating high capital intensity and potential reinvestment needs.

Geographical Breakdown of Revenue (2024)

Segments Breakdown of Revenue (2024)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.77 2.13
EV to Cash from Ops. EV/CFO 21.69 2.75
EV to Debt EV to Debt 3.64 17.25
EV to EBIT EV/EBIT -7.06 2.89
EV to EBITDA EV/EBITDA -48.42 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF -219.76 29.36
EV to Market Cap EV to Market Cap 1.20 25.09
EV to Revenue EV/Rev 0.78 32.80
Price to Book Value [P/B] P/B 1.20 4.73
Price to Earnings [P/E] P/E -4.46 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Int. cover (Qtr) -3.22 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 22.03 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 102.57 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 8.53 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 60.62 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) 6.94 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) -1.82 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) 3.19 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) 93.70 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 4.65 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.98 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 0.41 1.80
Current Ratio Curr Ratio (Qtr) 2.47 4.18
Debt to Equity Ratio Debt/Equity (Qtr) 0.40 1.20
Interest Cover Ratio Int Coverage (Qtr) -3.22 196.93
Times Interest Earned Times Interest Earned (Qtr) -3.22 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -1.20 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) -11.03 -2,478.60
EBT Margin % EBT Margin % (Qtr) -14.46 -2,690.42
Gross Margin % Gross Margin % (Qtr) 68.30 30.80
Net Profit Margin % Net Margin % (Qtr) -14.60 -2,821.53